Kexim invests in US drug developer
The Export-Import Bank of Korea (Kexim) is investing $10 million in Kolon Group's US-based drug-developing subsidiary TissueGene. It is Kexim's first equity investment in a drug developer.
The Export-Import Bank of Korea (Kexim) is investing $10 million in Kolon Group's US-based drug-developing subsidiary TissueGene. It is Kexim's first equity investment in a drug developer.